Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Price:
1.24 USD
7.83%
Updated:
May 16, 2024
P/E
Price to Earnings
Price to Earnings
-2.8
Current
-2.7
Median
27.4
Industry
Lower
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-2.8
Market Cap
/
316.9m
Net Income
-113.9m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| UK |
|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
316.9m USD | -2.8 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
289.2B USD | 60 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
171.1B USD | 45.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.7B USD | 31.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.8B USD | 27.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
138.6B AUD | 37.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
83.5B USD | 172.5 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
49.4B USD | -8.3 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
34.3B USD | 29.4 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.6T KRW | 74.7 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-4.5
2-Years Forward
P/E
-3.3
3-Years Forward
P/E
-2.8
You don't have any saved screeners yet
